Valuation
- Market cap
- 17,442,000
- Revenue TTM
- $0
- Net income TTM
- $-20,430,000
- P/E (trailing)
- 0.00
- P/E (forward)
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.00
Trading
- Volume
- 944,200
- Avg volume
- 788,574
- Day's range
- $0.43 – $0.52
- Shares out
- 33,414,000
- Stochastic %K
- 37%
- Beta
- 0.39
- Analysts
- Moderate Buy
- Price target
- $3.00
Company profile
Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven...
Show more
Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumor; and ETS2 driven diseases, including inflammatory bowel disease (IBD), primary sclerosing cholangitis, and ankylosing spondylitis. The company's lead development candidate is PAS-003, to treat amyotrophic lateral sclerosis. It also intends to develop PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 786 977 3380
- Website
- https://www.pasithea.com
- Address
- 1111 Lincoln Road, Suite 500, Miami Beach, United States
Latest news
No headlines yet.